Karyopharm Therapeutics (KPTI) Assets Average (2013 - 2025)

Karyopharm Therapeutics has reported Assets Average for 13 years, with the latest figure at $102.3 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average fell 42.17% year-over-year to $102.3 million; the trailing twelve-month figure through Dec 2025 stood at $102.3 million (down 42.17% YoY), and the FY2025 full-year result was $136.4 million, down 32.61% from the prior year.
• Assets Average for Q4 2025 stood at $102.3 million, up from $100.6 million in the prior quarter.
• The five-year high for Assets Average was $342.0 million in Q1 2023, with the low at $100.6 million in Q3 2025.
• Historically, Assets Average has averaged $235.3 million across 5 years, with a median of $262.8 million in 2021.
• Annual changes were most pronounced in 2023 — Assets Average increased 16.42% — and 2025, when it slumped 50.15%.
• Karyopharm Therapeutics' Assets Average stood at $279.7 million in 2021, then rose by 5.36% to $294.7 million in 2022, then dropped by 13.4% to $255.2 million in 2023, then plunged by 30.66% to $176.9 million in 2024, then plunged by 42.17% to $102.3 million in 2025.
• The last three Assets Average figures came in at $102.3 million (Q4 2025), $100.6 million (Q3 2025), and $116.3 million (Q2 2025), per Business Quant data.